Literature DB >> 15527773

Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers.

Peter M H Heegaard1, Heidi Gertz Pedersen, James Flink, Ulrik Boas.   

Abstract

The prion protein (PrP) peptide 106-126 forms amyloid aggregates in vitro and this sequence is speculated to be involved in the formation of amyloid fibrils by the abnormally folded PrP protein (PrPSc) found in spongiform encephalopathies. It is shown here by incubation experiments in water using Thioflavin T (ThT) as a fluorescent probe for amyloid formation that changes in C-terminal charge, oxidation state and conformational stabilisation lead to large changes in amyloid forming behaviour (amyloidogenicity) of this peptide. Amyloid formation is favoured by a charged C-terminus and is strongly inhibited by oxidation. Furthermore, cationic dendrimers are shown to perturb peptide fibrillation in a process dependent on the nature of the charged groups on the dendrimer surface.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527773     DOI: 10.1016/j.febslet.2004.09.073

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Nanoparticles as catalysts for protein fibrillation.

Authors:  Vicki L Colvin; Kristen M Kulinowski
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

2.  Membrane Disruption Mechanism of a Prion Peptide (106-126) Investigated by Atomic Force Microscopy, Raman and Electron Paramagnetic Resonance Spectroscopy.

Authors:  Jianjun Pan; Prasana K Sahoo; Annalisa Dalzini; Zahra Hayati; Chinta M Aryal; Peng Teng; Jianfeng Cai; Humberto Rodriguez Gutierrez; Likai Song
Journal:  J Phys Chem B       Date:  2017-05-10       Impact factor: 2.991

Review 3.  Complex polyamines: unique prion disaggregating compounds.

Authors:  Surachai Supattapone; Justin R Piro; Judy R Rees
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

4.  Effects of lipid composition and phase on the membrane interaction of the prion peptide 106-126 amide.

Authors:  Jian Zhong; Chunhui Yang; Wenfu Zheng; Lixin Huang; Yuankai Hong; Lijun Wang; Yinlin Sha
Journal:  Biophys J       Date:  2009-06-03       Impact factor: 4.033

5.  Nanomedicine for prion disease treatment: new insights into the role of dendrimers.

Authors:  James M McCarthy; Dietmar Appelhans; Jörg Tatzelt; Mark S Rogers
Journal:  Prion       Date:  2013 May-Jun       Impact factor: 3.931

Review 6.  Dendrimers as Antiamyloid Agents.

Authors:  Svetlana A Sorokina; Zinaida B Shifrina
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

7.  Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).

Authors:  James M McCarthy; Markus Franke; Ulrike K Resenberger; Sibeal Waldron; Jeremy C Simpson; Jörg Tatzelt; Dietmar Appelhans; Mark S Rogers
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

Review 8.  Methionine oxidation within the prion protein.

Authors:  John Bettinger; Sina Ghaemmaghami
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.